Can early rhythm control save hearts in AF patients with leaky valves?

NCT ID NCT07607093

Recruiting now Disease control Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether starting rhythm control early—using drugs or procedures like ablation—can improve outcomes for people with both atrial fibrillation and tricuspid regurgitation (a leaky heart valve). About 5,800 participants will be randomly assigned to early rhythm control or usual care. The goal is to see if early treatment reduces the chance of heart-related death, heart failure, stroke, or needing valve surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anti-arrhythmic drugs (flecainide, propafenone, pilsicainide, sotalol, amiodarone, dronedarone), DC cardioversion, or catheter ablation
What this could lead to: If successful, this could show that early rhythm control reduces the risk of heart-related death, heart failure, stroke, or need for tricuspid valve surgery in these patients.
What could go wrong: This is a large but still ongoing study, and the benefits of early rhythm control in this specific group are unproven. The drugs and procedures carry risks like side effects or complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation tricuspid valve insufficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION (AF) TRICUSPID REGURGITATION (TR)

Contacts and locations

Locations

Samsung Medical Center
RECRUITING

Seoul, Seoul, 06351, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.